Actuate Therapeutics (ACTU) News Today $6.98 +0.29 (+4.33%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$7.02 +0.03 (+0.50%) As of 10/3/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACTU Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period What is HC Wainwright's Estimate for ACTU FY2025 Earnings?September 27, 2025 | americanbankingnews.comFY2025 Earnings Forecast for ACTU Issued By HC WainwrightSeptember 25, 2025 | marketbeat.comActuate Therapeutics' (ACTU) Buy Rating Reaffirmed at HC WainwrightSeptember 25, 2025 | americanbankingnews.comActuate Therapeutics (NASDAQ:ACTU) Earns "Buy" Rating from HC WainwrightSeptember 23, 2025 | marketbeat.comActuate announces corporate update on regulatory path for elraglusibSeptember 22, 2025 | msn.comActuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic CancerSeptember 22, 2025 | msn.comActuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming MonthsSeptember 22, 2025 | globenewswire.comActuate Therapeutics (NASDAQ:ACTU) Upgraded at Wall Street ZenSeptember 20, 2025 | marketbeat.comActuate Therapeutics (NASDAQ:ACTU) Trading Down 0.9% - Here's WhySeptember 19, 2025 | marketbeat.comActuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment OptionSeptember 12, 2025 | finance.yahoo.comActuate prices 2.14M shares at $7.00 in underwritten public offeringSeptember 11, 2025 | msn.comActuate Therapeutics Shares Drop After Public Offering PricesSeptember 10, 2025 | marketwatch.comActuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common StockSeptember 10, 2025 | globenewswire.comActuate Therapeutics announces public offering of common stockSeptember 9, 2025 | msn.comActuate Therapeutics Announces Proposed Public Offering of Common StockSeptember 9, 2025 | globenewswire.comResearch Analysts Set Expectations for ACTU Q3 EarningsAugust 30, 2025 | marketbeat.comB. Riley Upgrades Actuate Therapeutics (NASDAQ:ACTU) to Strong-BuyAugust 29, 2025 | marketbeat.comDelveInsight Business Research, LLP: GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsightAugust 28, 2025 | finanznachrichten.deGSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsightAugust 28, 2025 | finance.yahoo.comB. Riley Begins Coverage on Actuate Therapeutics (NASDAQ:ACTU)August 28, 2025 | marketbeat.comB. Riley Securities Initiates Coverage of Actuate Therapeutics (ACTU) with Buy RecommendationAugust 26, 2025 | msn.comActuate Therapeutics initiated with a Buy at B. RileyAugust 26, 2025 | msn.comWall Street Zen Downgrades Actuate Therapeutics (NASDAQ:ACTU) to SellAugust 25, 2025 | marketbeat.comQ3 EPS Forecast for Actuate Therapeutics Reduced by AnalystAugust 22, 2025 | marketbeat.comResearch Analysts Issue Forecasts for ACTU Q1 EarningsAugust 21, 2025 | marketbeat.comVoss Capital LP Boosts Stock Position in Actuate Therapeutics, Inc. $ACTUAugust 21, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Actuate Therapeutics (NASDAQ:ACTU)August 20, 2025 | marketbeat.comActuate Therapeutics (NASDAQ:ACTU) Releases Earnings Results, Misses Expectations By $0.11 EPSAugust 16, 2025 | marketbeat.comActuate Therapeutics, Inc.'s (NASDAQ:ACTU) largest shareholders are private equity firms with 62% ownership, institutions own 20%August 15, 2025 | finance.yahoo.comActuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic CancerAugust 6, 2025 | globenewswire.comCraig-Hallum Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)August 1, 2025 | theglobeandmail.comActuate: Elraglusib Continues To Deliver And Next Catalyst Is FDA Type B MeetingJuly 30, 2025 | seekingalpha.comActuate Therapeutics registers 1.33M shares for resale by investorsJuly 25, 2025 | msn.comActuate Therapeutics (NASDAQ:ACTU) Stock Price Up 0.5% - Still a Buy?July 18, 2025 | marketbeat.comActuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric SarcomasJuly 17, 2025 | globenewswire.comActuate Therapeutics, Inc. (NASDAQ:ACTU) Director Equity Cof Lp Bios Buys 71,428 SharesJuly 1, 2025 | insidertrades.comActuate Therapeutics, Inc.June 30, 2025 | cnn.comActuate Therapeutics, Inc. (NASDAQ:ACTU) Director Aaron G.L. Fletcher Purchases 71,428 SharesJune 30, 2025 | marketbeat.comActuate Therapeutics, Inc. (NASDAQ:ACTU) Director Leslie W. Kreis Purchases 71,428 SharesJune 30, 2025 | marketbeat.comEquity Cof Lp Bios Acquires 71,428 Shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU) StockJune 30, 2025 | marketbeat.comActuate Therapeutics Reports Promising Survival Outcomes in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - NasdaqJune 26, 2025 | nasdaq.comActuate Therapeutics (NASDAQ:ACTU) Shares Down 4.6% - Here's WhyJune 26, 2025 | marketbeat.comMyelofibrosis Market Poised for Strong Growth, Fueled by FDA Designations and Promising Clinical Outcomes | DelveInsightJune 24, 2025 | theglobeandmail.comActuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib TrialJune 24, 2025 | globenewswire.comActuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCOJune 20, 2025 | globenewswire.comActuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 17, 2025 | tmcnet.comActuate Therapeutics to be included in Russell 3000, Russell 2000 indexesJune 16, 2025 | seekingalpha.comActuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 16, 2025 | globenewswire.comActuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic CancerJune 4, 2025 | seekingalpha.comActuate Therapeutics shares highlights from KOL eventon elraglusib dataJune 3, 2025 | finance.yahoo.com Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACTU Media Mentions By Week ACTU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACTU News Sentiment▼0.000.54▲Average Medical News Sentiment ACTU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACTU Articles This Week▼02▲ACTU Articles Average Week Get the Latest News and Ratings for ACTU and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Actuate Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ARVN News Today KALV News Today SVRA News Today GOSS News Today ETON News Today OPT News Today AQST News Today IVA News Today CMPS News Today ESPR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACTU) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
